For UK healthcare professionals only.


Scan the QR code for prescribing and adverse event reporting information.


Jump into savings with confidence


Luforbec is now the most widely prescribed ICS/LABA pMDI in 28 ICBs and Health Boards across the UK (June 2025).1


Delivering savings of over £62 million for the NHS to date with millions in potential savings still available (vs Fostair list price).1,2


Scan the QR code to find out more


Adult asthma: Luforbec 100/6 & 200/6 are indicated in the regular treatment of asthma in adults where use of a combination ICS/LABA is appropriate. Luforbec 100/6 can be used as Maintenance and Reliever Therapy (MART) in appropriate adult asthma patients. COPD: Luforbec 100/6 is indicated for symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.3,4


References: 1. NHS Prescribing Data and Savings to Date Analysis Lupin DOF. 2. UK General Practice Prescribing Data May 2024 – June 2025. Lupin DOF. 3. Luforbec 100/6 Summary of Product Characteristics (SPC). Lupin Healthcare UK Limited. 4. Luforbec 200/6 Summary of Product Characteristics (SPC). Lupin Healthcare UK Limited.


UK-LUF-2509-00003 | September 2025


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48